EUVIMEDEuropean Health Evidence
Uhr 10/10Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

Cardiovascular Morbidity Following Definitive Chemoradiotherapy for Lung Cancer in an Appalachian Population

Vivian Salama, Joseph A. Schmidlen, John Christopher Knoth, Troy Nguyen, Aaron Naveen Joseph, Matthew Trotta, Ramon Alfredo Siochi, Raymond R. Raylman, Jeffrey Ryckman, Mohammed Almubarak, Christopher M. Bianco, David A. Clump, Mina F. Hanna, Phillip M. Pifer

Cancers · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Background/Objectives: Cardiovascular morbidity following definitive chemoradiotherapy (CRT) for lung cancer is a major concern in Appalachia due to high rates of smoking and pre-existing cardiovascular disease. This study characterized the cardiovascular burden following CRT in a real-world Appalachian population. Methods: A retrospective study was conducted among Appalachian patients with lung cancer treated with definitive CRT from 2013 to 2025. Cardiovascular adverse event (CVAE) incidence, spectrum, and temporal distribution were characterized. Kaplan–Meier and Cox regression analyses evaluated time to CVAE and overall survival (OS). Exploratory machine-learning (ML) models assessed CVAE and mortality prediction. Results: Fifty-one patients (59%) experienced a CVAE. NSTEMI (15/51, 29%) and pericardial disease (15/51, 29%) were most frequent, followed by arrhythmia (8/51, 16%). Ischemic events occurred predominantly within the first year, whereas pericardial events were concentrated within 2 years. Median CVAE-free survival was 22.6 months, with estimated cumulative CVAE occurrence of 28.3% at 1 year and 50.0% at 2 years. After adjustment for age, cardiovascular comorbidity, and M stage, heart V20 (HR, 1.024 per 1% increase; 95% CI, 1.005–1.044; p = 0.015) and V30 (HR, 1.031; 95% CI, 1.004–1.058; p = 0.025) were associated with increased CVAE hazard. Median OS was 29 months; pre-existing cardiovascular comorbidity was associated with mortality (HR range, 2.16–2.45). Exploratory ML showed limited CVAE prediction but moderate mortality discrimination after feature selection (maximum AUC, 0.71). Conclusions: Cardiovascular morbidity was common and accumulated over time following definitive CRT in this Appalachian cohort. These findings support attention to baseline cardiovascular risk, cardiac radiation exposure, and longitudinal cardiovascular surveillance.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Vivian Salama, Joseph A. Schmidlen, John Christopher Knoth, Troy Nguyen, Aaron Naveen Joseph, Matthew Trotta, Ramon Alfredo Siochi, Raymond R. Raylman, Jeffrey Ryckman, Mohammed Almubarak, Christopher M. Bianco, David A. Clump, Mina F. Hanna, Phillip M. Pifer
Quelle
Cancers
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2072-6694
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Vivian Salama, Joseph A. Schmidlen, John Christopher Knoth, Troy Nguyen, Aaron Naveen Joseph, Matthew Trotta, Ramon Alfredo Siochi, Raymond R. Raylman, Jeffrey Ryckman, Mohammed Almubarak, Christopher M. Bianco, David A. Clump, Mina F. Hanna, Phillip M. Pifer (2026). Cardiovascular Morbidity Following Definitive Chemoradiotherapy for Lung Cancer in an Appalachian Population. Cancers. https://doi.org/10.3390/cancers18172830
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1